{"id":"rebif-new-formulation-ibuprofen-prn","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site reactions"},{"rate":"30-40","effect":"Flu-like symptoms (fever, chills, myalgia)"},{"rate":"25-35","effect":"Headache"},{"rate":"20-30","effect":"Fatigue"},{"rate":"10-15","effect":"Depression"},{"rate":"10-20","effect":"Elevated liver enzymes"},{"rate":"5-10","effect":"Lymphopenia"}]},"_chembl":{"chemblId":"CHEMBL521","moleculeType":"Small molecule","molecularWeight":"206.28"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interferon beta-1a binds to interferon-beta receptors on immune cells, triggering JAK-STAT signaling that increases expression of anti-inflammatory genes and reduces pro-inflammatory cytokine production. This leads to decreased migration of immune cells across the blood-brain barrier and reduced demyelination in multiple sclerosis. The new formulation likely improves pharmacokinetics, tolerability, or dosing convenience compared to the original formulation.","oneSentence":"Rebif (interferon beta-1a) activates interferon signaling pathways to modulate immune responses and reduce inflammation in the central nervous system.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:12.912Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing-remitting multiple sclerosis"},{"name":"Secondary progressive multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT00619307","phase":"PHASE3","title":"Transition to Rebif New Formulation","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2007-07","conditions":"Relapsing Multiple Sclerosis","enrollment":117}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Rebif New Formulation + ibuprofen PRN","genericName":"Rebif New Formulation + ibuprofen PRN","companyName":"Merck KGaA, Darmstadt, Germany","companyId":"merck-kgaa-darmstadt-germany","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rebif (interferon beta-1a) activates interferon signaling pathways to modulate immune responses and reduce inflammation in the central nervous system. Used for Relapsing-remitting multiple sclerosis, Secondary progressive multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}